329 related articles for article (PubMed ID: 30909510)
21. Isolation and characterization of stem-like cells from a human ovarian cancer cell line.
Wang L; Mezencev R; Bowen NJ; Matyunina LV; McDonald JF
Mol Cell Biochem; 2012 Apr; 363(1-2):257-68. PubMed ID: 22160925
[TBL] [Abstract][Full Text] [Related]
22. Energetic regulation of coordinated leader-follower dynamics during collective invasion of breast cancer cells.
Zhang J; Goliwas KF; Wang W; Taufalele PV; Bordeleau F; Reinhart-King CA
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7867-7872. PubMed ID: 30923113
[TBL] [Abstract][Full Text] [Related]
23. Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer.
Scalici JM; Thomas S; Harrer C; Raines TA; Curran J; Atkins KA; Conaway MR; Duska L; Kelly KA; Slack-Davis JK
J Nucl Med; 2013 Nov; 54(11):1883-9. PubMed ID: 24029657
[TBL] [Abstract][Full Text] [Related]
24. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.
Gao C; Yao H; Liu H; Feng Y; Yang Z
BMC Cancer; 2019 Mar; 19(1):237. PubMed ID: 30876464
[TBL] [Abstract][Full Text] [Related]
25. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract][Full Text] [Related]
26. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
27. The role of reproductive hormones in epithelial ovarian carcinogenesis.
Gharwan H; Bunch KP; Annunziata CM
Endocr Relat Cancer; 2015 Dec; 22(6):R339-63. PubMed ID: 26373571
[TBL] [Abstract][Full Text] [Related]
28. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells.
Yang W; Kim D; Kim DK; Choi KU; Suh DS; Kim JH
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064635
[TBL] [Abstract][Full Text] [Related]
30. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
Kurman RJ; Shih IeM
Am J Surg Pathol; 2010 Mar; 34(3):433-43. PubMed ID: 20154587
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells.
Yu ZH; Liu T; Zhao YH; Huang YY; Gao YT
Tumour Biol; 2014 May; 35(5):4637-44. PubMed ID: 24408020
[TBL] [Abstract][Full Text] [Related]
32. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
34. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
[TBL] [Abstract][Full Text] [Related]
35. What makes cells move: Requirements and obstacles for leader cells in collective invasion.
Chen BJ; Tang YJ; Tang YL; Liang XH
Exp Cell Res; 2019 Sep; 382(2):111481. PubMed ID: 31247191
[TBL] [Abstract][Full Text] [Related]
36. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
38. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
[No Abstract] [Full Text] [Related]
39. Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c.
Fang Z; Li T; Chen W; Wu D; Qin Y; Liu M; Wu G; He L; Li H; Gu H
Exp Cell Res; 2019 Sep; 382(1):111462. PubMed ID: 31194976
[TBL] [Abstract][Full Text] [Related]
40. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]